Free Specialist in Blood Banking - SBB(ASCP) Practice Questions

Sample Practice Questions

Try these 10 sample questions from the Specialist in Blood Banking - SBB(ASCP) practice bank. Each includes the answer and explanation. Continue with the interactive practice above to review the full question set.

1. 1An otherwise eligible female allogeneic donor has hemoglobin of 12.2 g/dL (122 g/L). Under the June 2023 FDA donor requirements, what additional condition permits collection using this hemoglobin level?

   1. A. A prior donation with hemoglobin of at least 12.5 g/dL
   2. B. An FDA-acceptable procedure assuring safety with the alternative standard
   3. C. A routine donation interval twice as long as the standard interval
   4. D. A repeat hemoglobin measurement using an earlobe blood specimen

   Answer: B

   Explanation: The regulation permits the lower female range only "in accordance with a procedure that has been found acceptable for this purpose by FDA." A value of 12.2 g/dL falls in that alternative range. Prior results or a longer interval do not replace the required procedure; earlobe blood is unacceptable.

   Reference: 21 CFR § 630.10 — General donor eligibility requirements — § 630.10(f)(3)(i)(A)

2. 2Two parents have conventional ABO genotypes A/O and B/O. Assuming normal H expression and Mendelian segregation, what is the probability that their child will have group O blood?

   1. A. 0%
   2. B. 50%
   3. C. 25%
   4. D. 75%

   Answer: C

   Explanation: The text states, "A child receives one of the three alleles from each parent". The equally likely combinations here are A/B, A/O, B/O, and O/O. Only O/O gives group O under the stated assumptions, so the probability is 1/4.

   Reference: Blood Groups and Red Cell Antigens — Ch. 5, Background information—History, three-allele model paragraph

3. 3After a macrophage processes a foreign protein, which surface complex presents the resulting fragments to helper T cells?

   1. A. Peptide bound to an MHC class I molecule
   2. B. Peptide bound to an MHC class II molecule
   3. C. Intact protein bound to an Fc receptor
   4. D. Complement-coated protein bound to a C3b receptor

   Answer: B

   Explanation: The source describes antigenic fragments presented "together with MHCII". MHC class II presents processed peptide to helper T cells. Class I uses a different T-cell pathway; Fc and complement receptors bind opsonized material rather than form the peptide–MHC II recognition complex.

   Reference: Blood Groups and Red Cell Antigens — Ch. 3, Antigen processing

4. 4What is detected in ABO forward grouping with anti-A and anti-B?

   1. A. A and B antigens on the tested red cells
   2. B. Anti-A and anti-B in the tested plasma
   3. C. IgG coating the tested red cells
   4. D. Soluble H substance in the tested plasma

   Answer: A

   Explanation: FDA describes determination of "erythrocytic antigens A and/or B". Forward grouping examines red-cell antigens; reverse grouping examines plasma antibodies.

   Reference: FDA: OLYMPUS PK Systems Blood Grouping and Phenotyping Reagents — Indication—Anti-A, Anti-B, and Anti-A,B

5. 5For a nonbleeding adult receiving myelosuppressive chemotherapy, the 2025 AABB/ICTMG recommendation uses which platelet-count threshold for prophylactic transfusion?

   1. A. Below 10 × 10^9/L
   2. B. Below 20 × 10^9/L
   3. C. Below 50 × 10^9/L
   4. D. Below 100 × 10^9/L

   Answer: A

   Explanation: The recommendation specifies "less than 10x103/µL". This equals 10 × 10^9/L for the stated nonbleeding chemotherapy setting.

   Reference: AABB Develops New Platelet Transfusion Guidelines — Recommendations—chemotherapy/allogeneic transplant

6. 6A calibration failure is discovered after patient results have been released. Under CLIA, which interval of results must be evaluated for possible adverse effect?

   1. A. Only results from the specimen that exposed the failure
   2. B. Results in the failed run and since the last acceptable run
   3. C. Only results reported after the failure was recognized
   4. D. Results from the last acceptable run, excluding later runs

   Answer: B

   Explanation: CLIA states: "All patient test results obtained in the unacceptable test run and since the last acceptable test run must be evaluated". The review extends backward to the last acceptable run, rather than beginning when the failure was recognized.

   Reference: 42 CFR 493.1282 — Corrective actions — § 493.1282(b)(2)

7. 7A prospective donor has a regular pulse of 46 beats/min. Under the June 2023 FDA rule, which action is required to use the exception to the usual pulse limits?

   1. A. Donor self-certification that athletic training explains the low pulse
   2. B. Interviewer documentation of a repeat pulse without physician review
   3. C. Responsible-physician documentation that donation will not harm the donor
   4. D. Collection-staff approval based on an acceptable hemoglobin result

   Answer: C

   Explanation: The rule allows an out-of-range pulse only "when the responsible physician determines and documents that the health of the donor would not be adversely affected by donating." Athletic history, repeat measurement alone, and acceptable hemoglobin do not provide that determination.

   Reference: 21 CFR § 630.10 — General donor eligibility requirements — § 630.10(f)(4)

8. 8How does the common ABO O allele containing the guanine deletion at position 261 prevent A-antigen synthesis?

   1. A. It introduces a frameshift that produces an inactive transferase
   2. B. It produces a transferase that preferentially adds galactose
   3. C. It increases degradation of a normally synthesized A antigen
   4. D. It deletes the entire FUT1 locus needed to synthesize H antigen

   Answer: A

   Explanation: The deletion "causes a frameshift" and yields a protein "that lacks enzymatic activity". This is a loss of ABO transferase activity, not a change to B specificity, removal of A after synthesis, or deletion of FUT1.

   Reference: Blood Groups and Red Cell Antigens — Ch. 5, Molecular information—The ABO locus, p. 30

9. 9Which differentiated B-cell progeny directly secrete large amounts of antigen-specific antibody?

   1. A. Helper T cells
   2. B. Cytotoxic T cells
   3. C. Macrophages
   4. D. Plasma cells

   Answer: D

   Explanation: The text identifies "plasma cells that produce antibodies". Helper T cells support B-cell activation, while macrophages process antigen and cytotoxic T cells have a different effector function.

   Reference: Blood Groups and Red Cell Antigens — Ch. 3, Antigen processing

10. 10Which materials are reacted with patient plasma in conventional ABO reverse grouping?

    1. A. Anti-A and anti-B reagents
    2. B. Anti-IgG and anti-C3d reagents
    3. C. Known A1 and B reagent red cells
    4. D. Known D-positive and D-negative group O cells

    Answer: C

    Explanation: FDA identifies "REAGENT RED BLOOD CELLS (A1 and B)" for reverse/plasma grouping. These reveal expected ABO antibodies, rather than directly typing the patient's red-cell antigens.

    Reference: FDA: OLYMPUS PK Systems Blood Grouping and Phenotyping Reagents — Indication—PK System Reagent Red Blood Cells